» Articles » PMID: 38635031

Vascular Mimicry As a Facilitator of Melanoma Brain Metastasis

Overview
Publisher Springer
Specialty Biology
Date 2024 Apr 18
PMID 38635031
Authors
Affiliations
Soon will be listed here.
Abstract

Melanoma has the highest propensity among solid tumors to metastasize to the brain. Melanoma brain metastases (MBM) are a leading cause of death in melanoma and affect 40-60% of patients with late-stage disease. Therefore, uncovering the molecular mechanisms behind MBM is necessary to enhance therapeutic interventions. Vascular mimicry (VM) is a form of neovascularization linked to invasion, increased risk of metastasis, and poor prognosis in many tumor types, but its significance in MBM remains poorly understood. We found that VM density is elevated in MBM compared to paired extracranial specimens and is associated with tumor volume and CNS edema. In addition, our studies indicate a relevant role of YAP and TAZ, two transcriptional co-factors scarcely studied in melanoma, in tumor cell-vasculogenesis and in brain metastasis. We recently demonstrated activation of the Hippo tumor suppressor pathway and increased degradation of its downstream targets YAP and TAZ in a metastasis impaired cell line model. In the current study we establish the utility of anti-YAP/TAZ therapy in mouse models of metastatic melanoma whereby treatment effectively inhibits VM and prolongs survival of mice with MBM. The data presented herein suggest that VM may be an important and targetable mechanism in melanoma and that VM inhibition might be useful for treating MBM, an area of high unmet clinical need, thus having important implications for future treatment regimens for these patients.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.


Modulation of blood-tumor barrier transcriptional programs improves intratumoral drug delivery and potentiates chemotherapy in GBM.

Jimenez-Macias J, Vaughn-Beaucaire P, Bharati A, Xu Z, Forrest M, Hong J Sci Adv. 2025; 11(9):eadr1481.

PMID: 40009687 PMC: 11864199. DOI: 10.1126/sciadv.adr1481.


A Role for the Hippo/YAP1 Pathway in the Regulation of In Vitro Vasculogenic Mimicry in Glioblastoma Cells.

Roy M, Elimam R, Zgheib A, Annabi B J Cell Mol Med. 2024; 28(24):e70304.

PMID: 39718433 PMC: 11667753. DOI: 10.1111/jcmm.70304.

References
1.
Azad T, Ghahremani M, Yang X . The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry. Cells. 2019; 8(5). PMC: 6562567. DOI: 10.3390/cells8050407. View

2.
Wu Z, Bian Y, Chu T, Wang Y, Man S, Song Y . The role of angiogenesis in melanoma: Clinical treatments and future expectations. Front Pharmacol. 2023; 13:1028647. PMC: 9797529. DOI: 10.3389/fphar.2022.1028647. View

3.
Guddati A, Marak C . Pulmonary Lymphangitic Carcinomatosis due to Renal Cell Carcinoma. Case Rep Oncol. 2012; 5(2):246-52. PMC: 3369259. DOI: 10.1159/000339126. View

4.
Corrie P, Marshall A, Nathan P, Lorigan P, Gore M, Tahir S . Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2018; 29(8):1843-1852. PMC: 6096737. DOI: 10.1093/annonc/mdy229. View

5.
Caulfield J, Kluger H . Emerging Studies of Melanoma Brain Metastasis. Curr Oncol Rep. 2022; 24(5):585-594. DOI: 10.1007/s11912-022-01237-9. View